Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway
Chini, Claudia C.S. , Espíndola‐Netto, Jair Machado , Mondal, Gourish, Guerrico, Anatilde M. Gonzalez, Nin, Verónica , Escande, Carlos , Sola‐Penna, Mauro , Zhang, Jin‐San , Billadeau, Daniel D. , Chini, Eduardo N. , Espindola-Netto, Jair M

Clinical Cancer Research | December 11, 2015 | Volume: 22 | Issue: 10 | Pages: 2496-2507

10.1158/1078-0432.ccr-15-1760 | PMID 26655844 Get It

Abstract Purpose: Recent studies suggest that SIRT1-activating compounds (STAC) are a promising class of anticancer drugs, although their mechanism of action remains elusive. The main goal of this study is to determine the role of STACs as a potential therapy for pancreatic cancer. In addition, we also explored the mechanism by which these compounds affect pancreatic cancer. Experimental design: Using in vitro (cell culture experiments) and in vivo (xenograft experiments) approaches, we studied the role of SIRT1 agonists (STAC) in human pancreatic cancer cell viability and growth. Results: We show that SIRT1 is highly expressed in pancreatic cancer cells and that the STACs SRT1720, SRT1460, and SRT3025 inhibited cell growth and survival of pancreatic cancer cells. STACs enhanced the sensitivity of pancreatic cells to gemcitabine and paclitaxel, indicating that these drugs could be used in combination with other chemotherapy drugs. We also show that STACs were very effective in inhibiting tumor xenograft growth. In mechanistic studies, we observed that STACs activated a SIRT1 lysosomal–dependent cell death. Furthermore, the effect of STACs on cell viability was also dependent on the expression of the endogenous SIRT1 inhibitor DBC1. Conclusions: Taken together, our results reveal an essential role for SIRT1 and lysosomes in the death pathway regulated by STACs in pancreatic cancer cells. Clin Cancer Res; 22(10); 2496–507. ©2015 AACR.
Longitudinal tracking of muscle sympathetic nerve activity and its relationship with blood pressure in subjects with prehypertension
Hering, Dagmara , Kára, Tomáš, Kucharska, W., Narkiewicz, Krzysztof , Somers, Virend K.

Blood Pressure | December 11, 2015 | Volume: 25 | Issue: 3 | Pages: 184-192

10.3109/08037051.2015.1121708 | PMID 26654200 Get It

Treatment of ruptured complex and large/giant ruptured cerebral aneurysms by acute coiling followed by staged flow diversion
Brinjikji, Waleed , Piano, Mariangela , Fang, Shanna, Pero, Guglielmo , Kallmes, David F. , Quilici, Luca , Valvassori, Luca , Lozupone, Emilio , Cloft, Harry J. , Boccardi, Edoardo , Lanzino, Giuseppe , Pero, Guglielmo

Journal of Neurosurgery | December 11, 2015 | Volume: 125 | Issue: 1 | Pages: 120-127

10.3171/2015.6.jns151038 | PMID 26654182 Get It

OBJECT Flow-diversion treatment has been shown to be associated with high rates of angiographic obliteration; however, the treatment is relatively contraindicated in the acute phase following subarachnoid hemorrhage (SAH) as these patients require periprocedural dual antiplatelet therapy. Acute coiling followed by flow diversion has emerged as an intriguing and feasible treatment option for ruptured complex and giant aneurysms. In this study the authors report outcomes and complications of patients with ruptured aneurysms undergoing coiling in the acute phase followed by planned delayed flow diversion. METHODS This case series includes patients from 2 institutions. All patients underwent standard endovascular coiling in the acute phase after SAH with the intention and plan to proceed with flow diversion at a later date. Outcomes studied included angiographic occlusion, procedure-related complications, and long-term clinical outcome as measured using the modified Rankin Scale. RESULTS A total of 31 patients underwent coiling in the acute phase with the intention to undergo flow diversion at a later date. The mean aneurysm size was 15.8 ± 7.9 mm. Of the 31 patients undergoing coiling, 4 patients could not undergo further flow-diverter therapy: 3 patients (9.7%) died of complications of subarachnoid hemorrhage and 1 patient had permanent morbidity as a result of perioperative ischemic stroke (3.1%). Twenty-seven patients underwent staged placement of flow diverters after adequate recovery. The median time to treatment was 16 weeks. There was one case of aneurysm rebleeding following coil treatment. There were no cases of permanent morbidity or mortality resulting from flow-diverter treatment. Twenty-four patients underwent imaging follow-up; 18 of these patients had aneurysms that were completely or nearly completely occluded (58.1% on an intent-to-treat basis). At last follow-up (mean 18.3 months), 25 patients had mRS scores ≤ 2 (80.6% on an intent-to-treat basis). CONCLUSIONS Staged treatment of ruptured complex and giant intracranial aneurysms with coiling in the acute phase and flow-diverter treatment following recovery from SAH is both safe and effective. In this series, no cases of rebleeding occurred during the interval between coiling and flow diversion. This strategy should be considered as a valid option in patients presenting with these challenging ruptured aneurysms.
Blockade of CCR2 reduces macrophage influx and development of chronic renal damage in murine renovascular hypertension
Kashyap, Sonu , Warner, Gina M., Hartono, Stella , Boyilla, Rajendra, Zubair, Adeel , Lien, Karen, Nath, Karl A. , Textor, Stephen C., Lerman, Lilach O. , Grande, Joseph P. , Hartono, Stella P, Knudsen, Bruce E. , Zubair, Adeel S.

American Journal of Physiology-Renal Physiology | December 11, 2015 | Volume: 310 | Issue: 5 | Pages: F372-F384

10.1152/ajprenal.00131.2015 | PMID 26661648 Get It

Renovascular hypertension (RVH) is a common cause of both cardiovascular and renal morbidity and mortality. In renal artery stenosis (RAS), atrophy in the stenotic kidney is associated with an influx of macrophages and other mononuclear cells. We tested the hypothesis that chemokine receptor 2 (CCR2) inhibition would reduce chronic renal injury by reducing macrophage influx in the stenotic kidney of mice with RAS. We employed a well-established murine model of RVH to define the relationship between macrophage infiltration and development of renal atrophy in the stenotic kidney. To determine the role of chemokine ligand 2 (CCL2)/CCR2 signaling in the development of renal atrophy, mice were treated with the CCR2 inhibitor RS-102895 at the time of RAS surgery and followed for 4 wk. Renal tubular epithelial cells expressed CCL2 by 3 days following surgery, a time at which no significant light microscopic alterations, including interstitial inflammation, were identified. Macrophage influx increased with time following surgery. At 4 wk, the development of severe renal atrophy was accompanied by an influx of inducible nitric oxide synthase (iNOS)+ and CD206+ macrophages that coexpressed F4/80, with a modest increase in macrophages coexpressing arginase 1 and F4/80. The CCR2 inhibitor RS-102895 attenuated renal atrophy and significantly reduced the number of dual-stained F4/80+ iNOS+ and F4/80+ CD206+ but not F4/80+ arginase 1+ macrophages. CCR2 inhibition reduces iNOS+ and CD206+ macrophage accumulation that coexpress F4/80 and renal atrophy in experimental renal artery stenosis. CCR2 blockade may provide a novel therapeutic approach to humans with RVH.
Missing Stowaways and Lack of Expected Concurrent Infections
Sasieta, Humberto C., Escalante, Patricio

Annals of the American Thoracic Society | December 11, 2015 | Volume: 12 | Issue: 12 | Pages: 1897-1898

10.1513/annalsats.201509-591le | PMID 26653199 Get It

Peer review fraud—it's not big and it's not clever
Rahman, Shamima , Baumgartner, Matthias R. , Patterson, Marc C. , Peters, Verena, Zschocke, Johannes , Patterson, Marc, Morava, Éva , Patterson, Marc , Baumgartner, Matthias

Journal of Inherited Metabolic Disease | December 11, 2015 | Volume: 39 | Issue: 1 | Pages: 1-2

10.1007/s10545-015-9905-x | PMID 26660661 Get It

Neurohistiocytosis of the Cerebellum: A Rare Cause of Ataxia
Elkouzi, Ahmad , Rauschkolb, Paula K., Grogg, Karen L., Gilchrist, James M.

Movement Disorders Clinical Practice | December 11, 2015 | Volume: 3 | Issue: 2 | Pages: 125-129

10.1002/mdc3.12277 | PMID 30363424 Get It

Abstract Erdheim‐Chester disease ( ECD ) is a non‐Langerhans cell histiocytosis that affects multiple body organs, notably the skeletal system. We examined a 58‐year‐old man who presented with ataxia and T2 hyperintensity of the middle cerebellar peduncles and dentate nuclei without contrast enhancement on MRI brain. Workup for malignancy revealed “hairy kidneys” on CT scan of the abdomen, and excisional biopsy of the retroperitoneal mass for concerns of lymphoma revealed foamy histiocytes that tested positive for CD 68 and negative for CD 1a, confirming the diagnosis of ECD . Further genetic testing on excised tissue revealed BRAF (V600E) gene mutation that is present in 50% of ECD patients. Treatment was initiated with targeted therapy using the BRAF inhibitor Dabrafenib. X‐ray of the lower extremities did not reveal sclerosis of the long bones, and bone scan with technetium 99 was negative except for a nonspecific tracer uptake in left calvarial bone with no corresponding CT changes or T1/T2 signal changes on MRI . His MRI brain revealed classic cerebellar involvement in ECD without other central nervous system ( CNS ) involvement. It has been postulated that bone involvement is almost universal in ECD ; however, our patient with ECD had ataxia and cerebellar involvement without significant bone involvement, as evidenced by bone scan. This is a rare presentation of ECD affecting the CNS and sparing the skeletal system. It confirms the wide spectrum of presentation this multisystem disease can have.
Diaphragmatic breathing for rumination syndrome: efficacy and mechanisms of action
Halland, Magnus , Parthasarathy, Gopanandan , Bharucha, Adil E. , Katzka, David A.

Neurogastroenterology & Motility | December 11, 2015 | Volume: 28 | Issue: 3 | Pages: 384-391

10.1111/nmo.12737 | PMID 26661735 Get It

AbstractBackgroundWhile high resolution esophageal manometry combined with impedancometry has demonstrated that gastric pressurizations lead to rumination, the contribution of upper esophageal sphincter (UES) and esophagogastric junction (EGJ) function to rumination is unclear. Behavioral therapy with diaphragmatic breathing (DB) can reduce rumination. We aimed to evaluate the pressures in the stomach, EGJ and UES during rumination and the effects of DB augmented with biofeedback therapy.MethodsSixteen patients with rumination were studied with manometry and impedancometry before and after a meal. The postprandial assessment comprised three periods: before, during, and after DB augmented with biofeedback therapy.Key ResultsAll patients had postprandial rumination, which was associated (p < 0.001) with increased gastric pressure and reversal of the postprandial gastroesophageal pressure gradient from −4 (−43 to 18) before to 20 (7–79) mmHg during rumination. The EGJ pressure was lower (p < 0.001) during gastric pressurizations that were associated with rumination vs those that were not. The UES also relaxed, almost completely, during rumination. Patients had a median (range) of 5 (2–10) rumination episodes before, 1 (0–2) (p < 0.001) during, and 3 (1–5) after (p < 0.001 vs during) diaphragmatic breathing. During manometry and impedancometry, DB was well‐tolerated and learned within 5 min. Diaphragmatic breathing increased EGJ pressure (p < 0.001) and restored a negative gastroesophageal pressure gradient (−20 mmHg [−80 to 7]).Conclusions & InferencesDiaphragmatic breathing aided with high resolution esophageal manometry is well‐tolerated, effective and averts the gastroesophageal pressure disturbance that leads to rumination.
A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG‐ACRIN cancer research group (E1908)
Wang, Victoria , Ketterling, Rhett P. , Hanson, Curtis A. , Libby, Edward N., Call, Timothy G. , Chang, Julie E., Liu, Jane J., Calvo, Alejandro , Rowe, Jacob M. , Luger, Selina M. , Litzow, Mark R. , Tallman, Martin S. , Zent, Clive S. , Barrientos, Jacqueline C. , Chang, Julie E., Lazarus, Hillard M. , Ketterling, Rhett P

American Journal of Hematology | December 11, 2015 | Volume: 91 | Issue: 3 | Pages: 308-312

10.1002/ajh.24265 | PMID 26662208 Get It

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) patients requiring initial therapy are often older and frailer and unsuitable candidates for standard chemoimmunotherapy regimens. Shorter duration combination monoclonal antibody (mAb) therapy using alemtuzumab and rituximab has been shown to be effective and tolerable treatment for CLL. Standard dose anti‐CD20 mAb therapy causes loss of CD20 expression by surviving CLL cells, which can be minimized by decreasing the mAb dose. We report a randomized phase II clinical trial enrolling older (≥ 65 years) patients (median age 76 years, n = 31) with treatment naïve progressive CLL. Patients received 8‐12 weeks of standard subcutaneous alemtuzumab with either intravenous standard (375 mg/m2 weekly)(n = 16) or low dose (20 mg/m2 3x week)(n = 15) rituximab. This study was closed before full accrual because the manufacturer withdrew alemtuzumab for treatment of CLL. The overall response rate was 90% with an 45% complete response rate, median progression‐free survival of 17.9 months and no significant differences in outcome between the low and standard dose rituximab arms. The major toxicities were cytopenia and infection with one treatment fatality caused by progressive multifocal leukoencephalopathy but no other opportunistic infections. Combination mAb therapy was effective and tolerable treatment for older and frailer patients with progressive CLL, achieving a high rate of complete remissions. These data support the role of mAb in therapy for less fit CLL patients and the further study of low dose higher frequency anti‐CD20 mAb therapy as a potentially more effective use of anti‐CD20 mAb in the treatment of CLL. Am. J. Hematol. 91:308–312, 2016. © 2015 Wiley Periodicals, Inc.
Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis
Patnaik, Mrinal M. , Finke, Christy M. , Pardanani, Animesh , Tefferi, Ayalew , Lasho, Terra L.

American Journal of Hematology | December 11, 2015 | Volume: 91 | Issue: 3 | Pages: No page available

10.1002/ajh.24267 | PMID 26662677 Get It